Tobira reports positive results from Phase l study of cenicriviroc to treat liver cirrhosis

Biopharmaceutical company Tobira Therapeutics has reported positive results from a Phase l study of cenicriviroc (CVC) in patients with liver cirrhosis and mild (Child-Pugh A) or moderate (Child-Pugh B) hepatic impairment.
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news